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Synopsis
Inhibitors of the aromatase enzyme represent a class of therapeutic agents which potently inhibit oestrogen
biosynthesis in vivo. This inhibition of oestrogen biosynthesis is well established as effective therapy in the
treatment of oestrogen-dependent breast cancer. CGS 16949A [4-(5,6,7,8-tetrahydroimidazo-[l,5-a]pyri-
din-5-yl)-benzonitrile hydrochloride] is a non-steroidal imidazole derivative which is a potent competitive
aromatase inhibitor in vitro. At a maximally effective concentration, it selectively inhibits aromatase and
does not affect glucocorticoid production from the adrenal in vitro.
In vivo in the rat, CGS 16949A effectively reduces ovarian oestrogen content and potently inhibits an
aromatase-mediated androgen-induced uterine hypertrophy. Oral treatment of adult, cyclic female rats
with CGS 16949A disrupts cyclicity, inhibits ovulation, reduces uterine weight and suppresses serum
oestradiol, all expected sequelae of oestrogen deprivation. At maximally effective doses, there is no
evidence of adrenal hypertrophy, indicating that adrenal steroidogenesis is unaffected. In the DMBA-
induced mammary carcinoma model in the rat, CGS 16949A caused almost complete regression of
palpable tumours and significantly suppressed the appearance of new tumours at a maximally effective oral
dose. Thus, CGS 16949A is a potent and selective inhibitor of the aromatase enzyme. In the rat, it is very
efficacious in inhibiting oestrogen biosynthesis and in suppressing the growth of DMBA-induced
mammary tumours.
Introduction
In the overall scheme of mammalian steroidogenesis, aromatase is the enzyme
complex which effects the last step in the biosynthesis of oestrogens from the steroidal
precursor cholesterol (Fig. 1). In the female, aromatase is located most importantly in
the ovary, adipose tissue, breast, brain and liver. In the adult premenopausal woman,
the ovary is the predominant source of circulating oestrogens and thus is the tissue
with the highest amount of aromatase. In the postmenopausal woman, the major
source of circulating oestrogens has been shown to be from the conversion of adrenal
androgens to oestrogens by aromatase in peripheral tissues like adipose tissue
including the breast (Grodin et al. 1973). Thus aromatase is a key enzyme in the
biosynthesis of oestrogens both in premenopausal and postmenopausal women.
Inhibition of the enzymatic activity of aromatase leads to a reduction in oestrogen
biosynthesis. In the premenopausal woman, this reduction in ovarian biosynthesis
can be overcome by a compensatory increase in circulating gonadotrophins resulting
from a functional feedback system. In the postmenopausal woman, however, extra-
ovarian oestrogen biosynthesis is not under feedback control, thus reductions in
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Figure 1. A composite of the main pathways of mammalian steroidogenesis.
circulating oestrogens can be maintained through the inhibition of aromatase.
Like several other steroidogenic enzymes, aromatase is a cytochrome P-450
dependent enzyme. Some inhibitors of aromatase are compounds which bind and
thus inhibit this component of the aromatase enzyme system, making them potential
inhibitors of other steroidogenic enzymes.
Since inhibition of aromatase could be a highly effective way of reducing the
concentrations of circulating oestrogens, it would also be effective therapy in the
treatment of oestrogen-dependent disease, the most important of which is oestrogen-
dependent breast cancer. Thus the past two decades have seen the synthesis and
development of pharmacological agents which potently inhibit aromatase in a highly
selective way.
Chemistry of aromatase inhibitors
Inhibitors of the aromatase enzyme are basically of two chemical types. They are
either derivatives of steroids which act as competitive inhibitors of the natural
aromatase enzyme substrate androstenedione, or they are non-steroidal in nature and
may bind, in addition, to the cytochrome P-450 of the aromatase enzyme complex.
Aminoglutethimide (a non-steroidal compound) and testolactone (a steroidal com-
pound) were first identified as being inhibitors of aromatase in the mid 1970s
(Thompson & Siiteri 1974; Siiteri & Thompson 1975, respectively). They had been
developed, however, as an inhibitor of adrenal steroidogenesis and an androgen
antagonist, respectively, and were already in use as therapeutic agents in the
treatment of metastatic breast cancer, although it was not until much later that their
aromatase-inhibiting properties were identified. Since then there has been a large
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number of compounds synthetised based on the structure of aminoglutethimide
(Daly et al. 1986; Hartmann & Batzl 1986) and also a large number of steroidal
compounds (Johnston & Metcalf 1984; Henderson et al. 1986) which have been
synthetised as aromatase inhibitors. The first studies of steroidal compounds
structurally designed to be aromatase inhibitors were reported by Schwarzel et al.
1973. These were followed by two reports characterising 4-hydroxy-androstenedione
as a potent aromatase inhibitor (Brodie et al. 1976; Brodie et al. 1977). Very recently,
a new imidazole derivative, CGS 16949A, has been synthetised which shows
extremely high potency as an aromatase inhibitor (Browne et al. 1986; Steele et al.
1987). The chemical structures of four of these compounds are shown in Figure 2.
Our efforts were directed to the synthesis of non-steroidal aromatase inhibitors
which, among other criteria, were potent, selective and efficacious in their inhibition
of the aromatase enzyme.
Potency and selectivity in vitro
Potency of aromatase inhibitors is usually assessed in an in vitro system using human
placenta as the source of the aromatase enzyme and then measuring the inhibition of
the aromatisation of the natural substrate androstenedione to the oestrogen oestrone.
This aromatisation reaction can either be followed by measuring the amount of
tritiated water released when a tritiated substrate, l/?,2/?-3H-androstenedione, is
aromatised to oestrone, as reported by Thompson & Siiteri 1974, or by isolating the
14C-labelled oestrogens which result when 14C-androstenedione is aromatised. Using
the latter product isolation method, compounds were assessed for their ability to
inhibit aromatase. The results are expressed as the concentrations at which they
inhibited the conversion of androstenedione to oestrogens by 50% (IC50) and as the
Aminoglutethimide
4-OH-Androstenedione
N=C HCI
Testolactone CGS 16949A
Figure 2. Chemical structures of nonsteroidal and steroidal aromatase inhibitors.
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Table 1. Inhibition of human placental aromatase.
Inhibitor IC5 0 nM K, nM
Testolactone 8000 4600
Aminoglutethimide 1900 530
CGP 32349 62 20
CGS 16949A 5 1.4
classic inhibition constant (Kj) derived from a Lineweaver-Burk plot. The results are
shown in Table 1.
Testolactone is the least potent of the four compounds with an increase in potency
with aminoglutethimide, followed by 4-hydroxy-androstenedione (CGP 32349) and
CGS 16949A, the last two being about 30 and 400 times as potent, respectively, as
aminoglutethimide.
Aminoglutethimide, which is a potent aromatase inhibitor, also inhibits other
cytochrome P-450-dependent enzymes. Before the aromatase inhibiting properties of
aminoglutethimide were recognised, it was used as a pharmacological agent to effect
a so-called medical adrenalectomy. Thus although aminoglutethimide is a potent
inhibitor of aromatase, it was not selective in its action. We have recently reported a
method which assesses the degree of selectivity of an aromatase inhibitor (Hausler et
al. 1989). Briefly, in this in vitro method, steroidogenesis is stimulated by incubating
hamster ovarian slices with the gonadotrophin luteinising hormone (LH) in either the
presence or absence of the aromatase inhibitor being tested. The release of LH-
stimulated progesterone and oestradiol into the medium is then measured. A selective
inhibitor of aromatase will inhibit the production of oestradiol without inhibiting the
production of progesterone. Inhibition of adrenal steroidogenesis was also studied by
measuring the inhibition of adrenocorticotrophic hormone (ACTH)-induced corti-
costerone production in rat adrenal fragments in vitro by the method of Saffran &
Schally 1955.
Figure 3 represents results obtained with aminoglutethimide and CGS 16949A in
both these systems. These results, along with those for testolactone and 4-hydroxy-
androstenedione, have been reported in detail elsewhere (Hausler et al. 1989).
In brief, testolactone, aminoglutethimide, 4-hydroxy-androstenedione and CGS
16949A inhibit the production of oestradiol by 50% (IC50) at concentrations of 130,
13, 0.88 and 0.03 fiM, respectively. Progesterone production is inhibited at concentra-
tions (IC50) of 1000, 60, >330 and 160 JXM, respectively. Thus, not only is CGS
16949A by far the most potent of the four aromatase inhibitors, it is also highly
selective as it only inhibits progesterone at concentrations which are over 5000 times
higher than those required for inhibiting oestradiol production. This selectivity is
further corroborated from results obtained for the inhibition of ACTH-induced
corticosterone production in rat adrenals which are also shown in Figure 3. Here,
aminoglutethimide inhibits corticosterone production with an IC50 of 50 /zM, which
is similar to that needed for inhibiting progesterone (60 fiM) displaying a relative lack
of selectivity. On the other hand, CGS 16949A only inhibits corticosterone produc-
tion with an IC50 of 100 yuM which is 3000 times higher than the IC50 for inhibiting
oestrogen production (0.03 /JM). Thus in vitro, CGS 16949A is by far the most potent
of the four aromatase inhibitors and also highly selective in its inhibition of
aromatase.
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Figure 3. Inhibition in vitro of LH-stimulated oestradiol and progesterone production in hamster ovarian
slices (panels to the left), and of ACTH-stimulated corticosterone production in rat adrenal
fragments (panels to the right) by CGS 16949A and aminoglutethimide phosphate; shaded areas
in the panels on the right represent concentrations at which oestradiol production is inhibited in
hamster ovarian slices shown on the left; redrawn partly from data reported in Hausler et al.
1989.
Efficacy in vivo
Inhibition of ovarian oestrogen content
Steele et al. (1987) have recently reported that CGS 16949A maximally inhibits rat
ovarian oestrogen synthesis at an oral dose of 0.26 mg/kg. In the same model,
aminoglutethimide produces a similar effect at an oral dose of 100 mg/kg. The
minimum effective dose of CGS 16949 A required to elicit this inhibition of oestrogen
synthesis was 0.003 mg/kg. In this model, CGS 16949A is about 400 times as
efficacious as aminoglutethimide.
Inhibition of aromatase-mediated androgen-induced uterine hypertrophy
Knudsen & Mahesh (1975) had shown that a variety of androgens elicited a
uterotrophic effect in immature female rats. They were able to show that this
oestrogen-like effect was mediated by aromatase in the immature female rat ovary
and could be antagonised by ovariectomy. We reasoned that, like ovariectomy,
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Figure 4. Effects of CGS 16949A and aminoglutethimide phosphate administered p.o. concomitantly
with androstenedione (30 mg/kg s.c), once daily for four days to immature female rats, on
uterine wet weight (mean + SEM, N = 5 for each treatment group).
aromatase inhibitors should also be able to antagonise these effects. Immature female
rats were treated with androstenedione (30 mg/kg s.c.) for four days in the absence or
presence of varying oral doses of either aminoglutethimide or CGS 16949A. The
results are shown in Figure 4. Both aromatase inhibitors cause a dose-dependent
antagonism of the induced uterine hypertrophy. In this model CGS 16949A is about
1000 times as potent as aminoglutethimide.
Effects of a fourteen-day treatment with CGS 16949A in adult cyclic female rats
CGS 16949A was administered orally, once daily at doses of 0.1, 0.3 and 3.0 mg/kg
for fourteen days. Four hours after the last dose on the fourteenth day, the animals
were killed and trunk blood taken for measurement of serum oestradiol, luteinising
hormone and prolactin by specific radioimmunoassays. The uterus, ovaries, pitui-
tary, adrenals, thyroid and liver were removed and weighed. During the course of the
fourteen-day adminstration schedule, daily vaginal smears were taken.
Results of the vaginal cytology (data not shown) indicated that there was a dose-
related disruption in ovarian cyclicity in the treated animals. All the animals in the
highest dose group showed diestrus smears after the fourth day of treatment. The
changes in organ weights are shown in Figure 5. There is a dose-dependent
suppression of both uterine and pituitary weights which assumes statistical signifi-
cance at the highest dose. Ovarian weights are significantly but not dose-dependently
increased. There was no effect on adrenal, thyroid or liver weights. Serum hormone
concentrations shown in Figure 6 demonstrate a significant decrease in serum
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Figure 5. Effect of a once-daily fourteen-day oral treatment with CGS 16949A on relative organ weights
in adult female rats; results are expressed as mean ± SEM (N = 8 for each treatment group).
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Figure 6. Serum hormone concentrations in adult female rats at the end of a fourteen-day oral treatment
with CGS 16949A; results are expressed as mean + SEM for each hormone; rat luteinising
hormone and rat prolactin are expressed in terms of the reference standards NIAMD-rLH-RP-
1 and NIAMD-rat prolactin-RP-1, respectively; these standards and the accompanying RIA
reagents were generously supplied by the NIAMD/NIH, USA.
, available at https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0269727000010769
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 11:39:48, subject to the Cambridge Core terms of use
300 A jay S. Bhatnagar et al.
oestradiol and prolactin at the highest dose and a dose-dependent increase in serum
luteinising hormone.
Thus CGS 16949A exhibits potent oestrogen-lowering effects in a dose-dependent
manner in adult cyclic female rats. This suppression of oestrogen is-manifest by a
significant reduction in serum oestradiol, a consequent reduction in uterine weight,
disruption of ovarian cyclicity and the presence of prolonged periods of diestrus.
Further, the reduction in circulating serum oestradiol leads to a decrease in serum
prolactin and a distinct elevation in serum luteinising hormone, which in turn leads to
an increase in ovarian weight.
Anti-tumour efficacy in vivo
Schieweck et al. (1988) have recently reported on the effects of CGS 16949A on the
growth of the dimethylbenzanthracene (DMBA)-induced mammary carcinoma in
adult female rats. Rats bearing DMBA-induced mammary tumours were treated
orally for forty-two days with varying doses of CGS 16949A. The results of one such
treatment are shown in Figure 7. CGS 16949A at a maximal dose of 1 mg/kg caused
almost complete regression of tumours existing at the start of the experiment and also
significantly suppressed the appearance of new tumours during the course of the
experiment. The tumour-regressing effects were dose-dependent with a 50% effective
dose (ED50) of about 0.1 mg/kg. Under the same experimental conditions, aminoglu-
tethimide at its maximal tolerated dose of 100 mg/kg was only marginally effective.
This marked anti-tumour effect of CGS 16949A in the DMBA model led us to
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Figure 7. Effect of oral administration of CGS 16949A on mean tumour volume of DMBA-induccd
mammary tumours in adult female rats; redrawn from data reported in Schieweck el al. 1988;
N= 15 for each treatment group.
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compare these effects with those of the anti-oestrogen, tamoxifen, in the same model.
The results of one such experiment are shown in Figure 8. Although most of the
reported studies with tamoxifen in the DMBA model have administered the
compound subcutaneously (e.g. Jordan 1976; Jordan & Allen 1980), the oral doses of
tamoxifen used in our studies were extrapolated from the effective subcutaneous
doses and were also comparable to the oral dose administered in one reported study
(Fiebig & Schmahl 1977). It is apparent from the results in Figure 8 that CGS 16949A
is far more efficacious than tamoxifen in causing the regression of DMBA-induced
mammary tumours.
It appears from Figures 7 and 8 that after three weeks of treatment, mean tumour
volume increases. This is due to three of a total of twenty-seven tumours in the
1 mg/kg group of fifteen animals which grew rapidly and are termed hormone-
independent. After three weeks, as the hormone-dependent tumours become smaller,
the three hormone-independent tumours disproportionately contribute to the mean
tumour volume. If these three tumours were disregarded in the statistical analysis,
mean tumour volume in both the 0.5 and the 1 mg/kg treatment groups would remain
suppressed until the end of treatment. Furthermore, serum oestradiol was signifi-
cantly suppressed at the end of treatment. Details, including statistical analysis, were
reported previously (Schieweck et al. 1988).
During all of the forty-two day treatment schedules used in the anti-tumour
studies, CGS 16949A was very well tolerated at doses higher than the maximally
effective dose. In contrast, treatment with aminoglutethimide at its maximally
tolerated dose was only marginally effective.
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Figure 8. Effects of oral administration of various closes of tamoxifen and a maximal dose of CGS
16949A on mean tumour volume in DMBA-induced mammary tumours in adult female
rats; partly redrawn from data reported in Schieweck et al. 1988; N = 10 for each treatment
group.
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Conclusions
The results presented above profile CGS 16949A as a very potent, non-steroidal
competitive inhibitor of the aromatase enzyme system. Both in vitro and in vivo, CGS
16949A very effectively inhibits the conversion of androgens to oestrogens. In vitro
CGS 16949A is very selective in its inhibition of aromatase, only inhibiting other
steroidogenic cytochrome P-450-dependent enzymes at concentrations which are
orders of magnitude higher than those required for inhibition of aromatase. In vivo,
in female rats, this inhibition of oestrogen biosynthesis is manifest in reductions in
ovarian oestrogen content and uterine weight, suppression of serum oestradiol and
prolactin, an increase in serum luteinising hormone and suppression of the growth of
DMBA-induced mammary tumours. The ED5 0 for most of these effects lie in the
range of 0.025-0.1 mg/kg. In this dose range, no adrenal hypertrophy or central
nervous system side-effects were observed.
In comparison to aminoglutethimide, CGS 16949A is 500-1000 times as potent in
its inhibition of aromatase and far more selective in its action. Inhibition of adrenal
steroidogenesis occurs with aminoglutethimide within its therapeutically-effective
dose range. With CGS 16949A, there appears to be no inhibition of adrenal
steroidogenesis in vivo within its effective dose range. The dissociation of these side
effects from the desired therapeutic efficacy distinctly characterises the pharmacologi-
cal profile of CGS 16949A. Thus CGS 16949A promises to be an effective therapeutic
agent for the treatment of oestrogen-dependent diseases, of which one of the most
important is oestrogen-dependent breast cancer.
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